Publications by authors named "Christopher Zimmer"

21Publications

New approach to investigate the cytotoxicity of nanomaterials using single cell mechanics.

J Phys Chem B 2014 Feb 23;118(5):1246-55. Epub 2014 Jan 23.

Department of Chemistry, University of California, Davis , One Shields Avenue, Davis, California 95616, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jp410764fDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980960PMC
February 2014

Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.

Am J Health Syst Pharm 2011 Feb;68(4):328-33

Health Economics and Outcomes Research, Boston Healthcare Associates, Inc., MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp100217DOI Listing
February 2011

Single-cell mechanics provides a sensitive and quantitative means for probing amyloid-beta peptide and neuronal cell interactions.

Proc Natl Acad Sci U S A 2010 Aug 19;107(31):13872-7. Epub 2010 Jul 19.

Department of Chemistry, University of California, Davis, CA 95616, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1008341107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922280PMC
August 2010

Effects of tolvaptan on dyspnoea relief from the EVEREST trials.

Eur Heart J 2009 Sep 27;30(18):2233-40. Epub 2009 Jun 27.

Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehp253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742783PMC
September 2009

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.

Eur Heart J 2009 Jul 2;30(13):1666-73. Epub 2009 May 2.

Division of Cardiology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair, Suite 600, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehp144DOI Listing
July 2009

Use of photolithography to encode cell adhesive domains into protein microarrays.

Langmuir 2008 Mar 17;24(5):2232-9. Epub 2008 Jan 17.

Department of Biomedical Engineering and Chemistry, University of California, Davis, Davis, California 95616, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/la702883dDOI Listing
March 2008

Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.

J Cardiovasc Pharmacol 2007 Aug;50(2):213-22

Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD 20850, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0b013e318074f934DOI Listing
August 2007

Tolvaptan for the treatment of hyponatremia and congestive heart failure.

Future Cardiol 2006 Nov;2(6):627-34

Otsuka Maryland Research Institute, Clinical Development Department, 2440 Research Boulevard, Rockville, MD 20850 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/14796678.2.6.627DOI Listing
November 2006

Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure.

J Cardiovasc Pharmacol 2005 Nov;46(5):609-14

Saint Louis University Health Sciences Center, 3635 Vista Avenue, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.fjc.0000180899.24865.b6DOI Listing
November 2005

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.

Am J Physiol Renal Physiol 2006 Feb 27;290(2):F273-8. Epub 2005 Sep 27.

Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and College of Medicine, 200 First St. SW, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajprenal.00195.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2647140PMC
February 2006

Role of vasopressin antagonists in the management of acute decompensated heart failure.

Curr Heart Fail Rep 2005 Sep;2(3):131-9

Department of Clinical Development, Otsuka Maryland Research Institute, Inc., 2440 Research Boulevard, Rockville, MD 20850, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11897-005-0021-3DOI Listing
September 2005